- ASSOCIATE PROFESSOR Psychiatry
- ASSOCIATE PROFESSOR Neuroscience
Yale-New Haven Psychiatric Hospital
Katherine E. Burdick, Ph.D. is an Associate Professor of Psychiatry and Neuroscience at Mount Sinai School of Medicine and Chief of Neurocognitive Research in the Department of Psychiatry. She received her PhD from the The Graduate Center, City University of New York and completed her clinical internship and postdoctoral fellowship at the Yale University School of Medicine.
Dr. Burdick’s primary research interest is in neurocognitive dysfunction in major psychiatric disorders with a focus on understanding its underlying etiologies through genetics, neuroimaging, and novel treatment strategies. She has received funding from the National Institute of Mental Health (NIMH), the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD), and the Stanley Medical Research Institute to conduct her research. Dr. Burdick has authored more than 50 publications in this area, including the first published book focused on the cognitive deficits common in bipolar disorder. She is considered a leader in the field of cognitive genomics.
As a licensed clinical neuropsychologist, Dr. Burdick has extensive experience in the assessment of cognition in psychiatric and neurologic patients and she has more than 10 years of experience teaching in a university setting and in a medical school/residency training program, mentoring psychiatry residents, psychology interns, and postdoctoral fellows.
Gilbert AM, Garno JL, Braga RJ, Shaya Y, Goldberg TE, Malhotra AK, Burdick KE. Clinical and Cognitive Correlates of Suicide Attempts in Bipolar Disorder: Is Suicide Predictable?. Journal of Clinical Psychiatry 2011 July;.
Burdick KE, Gopin CB, Malhotra AK. Pharmacogenetic approaches to cognitive enhancement in schizophrenia. Harvard review of psychiatry; 19(3).
Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, Malhotra AK, Gu HH, Sadee W. Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2011 Jul; 36(8).
Burdick KE, Goldberg TE, Cornblatt BA, Keefe RS, Gopin CB, Derosse P, Braga RJ, Malhotra AK. The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2011 Jul; 36(8).
Gopin CB, Burdick KE, Derosse P, Goldberg TE, Malhotra AK. Emotional modulation of response inhibition in stable patients with bipolar I disorder: a comparison with healthy and schizophrenia subjects. Bipolar disorders 2011 Mar; 13(2).
Zhang JP, Burdick KE, Lencz T, Malhotra AK. Meta-analysis of genetic variation in DTNBP1 and general cognitive ability. Biological psychiatry 2010 Dec; 68(12).
Burdick KE, Goldberg JF, Harrow M. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up. Acta psychiatrica Scandinavica 2010 Dec; 122(6).
Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar disorders 2010 Jun; 12(4).
Burdick KE, DeRosse P, Kane JM, Lencz T, Malhotra AK. Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. The American journal of psychiatry 2010 Apr; 167(4).
Mahon K, Burdick KE, Szeszko PR. A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neuroscience and biobehavioral reviews 2010 Mar; 34(4).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Burdick during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Dainippon Sumitomo Pharma Co., Ltd.; Lundbeck Inc.; Takeda Pharmaceutical Company Limited
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Icahn Medical Institute Floor 4th Room L4-45
1425 Madison Avenue
New York, NY 10029
Icahn Medical Institute Floor 4th Room 42
1425 Madison Avenue
New York, NY 10029